CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival

S. M. Bagnasco, W. Tsai, M. H. Rahman, E. S. Kraus, Laura Barisoni-Thomas, R. Vega, L. C. Racusen, M. Haas, B. S. Mohammed, A. A. Zachary, R. A. Montgomery

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30% of all the biopsies showed CD20-positive clusters with more than 100 cells, 9% with more than 200 cells and 5% with more than 275 cells. Patients with B cell-rich (>100 or >200/HPF CD20-positive cells) and B cell-poor biopsies (<50 CD20-positive cells/HPF) were compared. Serum creatinine and eGFR of B cell-rich (CD20 > 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the >200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for >100/HPF, p = 0.9 for >200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.

Original languageEnglish
Pages (from-to)1968-1973
Number of pages6
JournalAmerican Journal of Transplantation
Volume7
Issue number8
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Graft Survival
Allografts
B-Lymphocytes
Kidney
Biopsy
Creatinine
Transplantation
Antibodies

Keywords

  • Acute rejection
  • B cells
  • CD20
  • Renal biopsy
  • Renal transplantation

ASJC Scopus subject areas

  • Immunology

Cite this

CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. / Bagnasco, S. M.; Tsai, W.; Rahman, M. H.; Kraus, E. S.; Barisoni-Thomas, Laura; Vega, R.; Racusen, L. C.; Haas, M.; Mohammed, B. S.; Zachary, A. A.; Montgomery, R. A.

In: American Journal of Transplantation, Vol. 7, No. 8, 01.08.2007, p. 1968-1973.

Research output: Contribution to journalArticle

Bagnasco, SM, Tsai, W, Rahman, MH, Kraus, ES, Barisoni-Thomas, L, Vega, R, Racusen, LC, Haas, M, Mohammed, BS, Zachary, AA & Montgomery, RA 2007, 'CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival', American Journal of Transplantation, vol. 7, no. 8, pp. 1968-1973. https://doi.org/10.1111/j.1600-6143.2007.01885.x
Bagnasco, S. M. ; Tsai, W. ; Rahman, M. H. ; Kraus, E. S. ; Barisoni-Thomas, Laura ; Vega, R. ; Racusen, L. C. ; Haas, M. ; Mohammed, B. S. ; Zachary, A. A. ; Montgomery, R. A. / CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival. In: American Journal of Transplantation. 2007 ; Vol. 7, No. 8. pp. 1968-1973.
@article{5e21a593618243fd87743fad65390b76,
title = "CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival",
abstract = "We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30{\%} of all the biopsies showed CD20-positive clusters with more than 100 cells, 9{\%} with more than 200 cells and 5{\%} with more than 275 cells. Patients with B cell-rich (>100 or >200/HPF CD20-positive cells) and B cell-poor biopsies (<50 CD20-positive cells/HPF) were compared. Serum creatinine and eGFR of B cell-rich (CD20 > 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the >200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for >100/HPF, p = 0.9 for >200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.",
keywords = "Acute rejection, B cells, CD20, Renal biopsy, Renal transplantation",
author = "Bagnasco, {S. M.} and W. Tsai and Rahman, {M. H.} and Kraus, {E. S.} and Laura Barisoni-Thomas and R. Vega and Racusen, {L. C.} and M. Haas and Mohammed, {B. S.} and Zachary, {A. A.} and Montgomery, {R. A.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1111/j.1600-6143.2007.01885.x",
language = "English",
volume = "7",
pages = "1968--1973",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - CD20-positive infiltrates in renal allograft biopsies with acute cellular rejection are not associated with worse graft survival

AU - Bagnasco, S. M.

AU - Tsai, W.

AU - Rahman, M. H.

AU - Kraus, E. S.

AU - Barisoni-Thomas, Laura

AU - Vega, R.

AU - Racusen, L. C.

AU - Haas, M.

AU - Mohammed, B. S.

AU - Zachary, A. A.

AU - Montgomery, R. A.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30% of all the biopsies showed CD20-positive clusters with more than 100 cells, 9% with more than 200 cells and 5% with more than 275 cells. Patients with B cell-rich (>100 or >200/HPF CD20-positive cells) and B cell-poor biopsies (<50 CD20-positive cells/HPF) were compared. Serum creatinine and eGFR of B cell-rich (CD20 > 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the >200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for >100/HPF, p = 0.9 for >200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.

AB - We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30% of all the biopsies showed CD20-positive clusters with more than 100 cells, 9% with more than 200 cells and 5% with more than 275 cells. Patients with B cell-rich (>100 or >200/HPF CD20-positive cells) and B cell-poor biopsies (<50 CD20-positive cells/HPF) were compared. Serum creatinine and eGFR of B cell-rich (CD20 > 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the >200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for >100/HPF, p = 0.9 for >200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.

KW - Acute rejection

KW - B cells

KW - CD20

KW - Renal biopsy

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=34447128734&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447128734&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2007.01885.x

DO - 10.1111/j.1600-6143.2007.01885.x

M3 - Article

VL - 7

SP - 1968

EP - 1973

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -